Mohammad Ghasem Kashanizadeh1, Fariba Rezaei Fakhrnezhad2, Saeede Yavari3, Homa Alizadeh4, Payam Hashemim5, Amir Monfaredan6. 1. Azad University of Medical Sciences, Tehran, Iran. 2. Department of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran. 3. Science and Research Branch, Department of Biology, Islamic Azad University, Tehran, Iran. 4. Department of Genetics, Faculty of Biological Sciences, Islamic Azad University North Tehran Branch, Tehran, Iran. 5. Faculty of Medicine, Tehran University of Medical Science, Tehran, Iran. 6. Department of Hematology, Faculty of Medicine, Tabriz Branch, Islamic Azad University, Tabriz, Iran.
Abstract
BACKGROUND: Prostate cancer is the second most common cancer in men in Iran. It can be treated in the early stages of the disease; therefore, early diagnosis can be lifesaving. The aim of this study was to investigate the molecular expression of some oncogenes and predisposing behaviors contributing to the aggressiveness of prostate cancer. METHODS: In this case-control study, prostate cancer specimens were collected from both patients and healthy volunteers. Several factors such as age, family history, smoking, and stage of the disease, were investigated based on the criteria of this study. Real-time PCR was used to measure the expression of four oncogenes. Statistical analysis of our data was carried out using SPSS software version 22. RESULTS: The X2 test showed that there was a difference in the incidence of prostate cancer in different age groups (X2= 9.30; p= 0.026). Although data analysis by the X2 test showed that family history had a significant effect on prostate cancer (X2= 14.43; p= 0.001), smoking did not show a significant effect on the incidence of this disorder (X2= 4.67; p= 0.097). The T2N1M0 stage is the most common form of prostate cancer in patients with family history of prostate cancer and the habit of smoking. Also, the expression of KRAS1P, GLB1L2, SChLAP1 and PACSIN3 oncogenes reduced in prostate cancer samples compared to the control group. CONCLUSION: Overall, functional interpretation of gene expression in the prostate tissue can affect tumor progression. Yet, further practical studies are required to reveal the accurate underlying mechanisms.
BACKGROUND: Prostate cancer is the second most common cancer in men in Iran. It can be treated in the early stages of the disease; therefore, early diagnosis can be lifesaving. The aim of this study was to investigate the molecular expression of some oncogenes and predisposing behaviors contributing to the aggressiveness of prostate cancer. METHODS: In this case-control study, prostate cancer specimens were collected from both patients and healthy volunteers. Several factors such as age, family history, smoking, and stage of the disease, were investigated based on the criteria of this study. Real-time PCR was used to measure the expression of four oncogenes. Statistical analysis of our data was carried out using SPSS software version 22. RESULTS: The X2 test showed that there was a difference in the incidence of prostate cancer in different age groups (X2= 9.30; p= 0.026). Although data analysis by the X2 test showed that family history had a significant effect on prostate cancer (X2= 14.43; p= 0.001), smoking did not show a significant effect on the incidence of this disorder (X2= 4.67; p= 0.097). The T2N1M0 stage is the most common form of prostate cancer in patients with family history of prostate cancer and the habit of smoking. Also, the expression of KRAS1P, GLB1L2, SChLAP1 and PACSIN3 oncogenes reduced in prostate cancer samples compared to the control group. CONCLUSION: Overall, functional interpretation of gene expression in the prostate tissue can affect tumor progression. Yet, further practical studies are required to reveal the accurate underlying mechanisms.
Entities:
Keywords:
Age; Family History; Oncogenes; Prostate Cancer; Smoking
Authors: Melvin L K Chua; Winnie Lo; Melania Pintilie; Jure Murgic; Emilie Lalonde; Vinayak Bhandari; Osman Mahamud; Anuradha Gopalan; Charlotte F Kweldam; Geert J L H van Leenders; Esther I Verhoef; Agnes Marije Hoogland; Julie Livingstone; Alejandro Berlin; Alan Dal Pra; Alice Meng; Junyan Zhang; Michèle Orain; Valérie Picard; Hélène Hovington; Alain Bergeron; Louis Lacombe; Yves Fradet; Bernard Têtu; Victor E Reuter; Neil Fleshner; Michael Fraser; Paul C Boutros; Theodorus H van der Kwast; Robert G Bristow Journal: Eur Urol Date: 2017-05-13 Impact factor: 20.096
Authors: Rohit Mehra; Aaron M Udager; Thomas U Ahearn; Xuhong Cao; Felix Y Feng; Massimo Loda; Joshua S Petimar; Philip Kantoff; Lorelei A Mucci; Arul M Chinnaiyan Journal: Eur Urol Date: 2015-12-24 Impact factor: 20.096
Authors: Steven Joniau; Alberto Briganti; Paolo Gontero; Giorgio Gandaglia; Lorenzo Tosco; Steffen Fieuws; Bertrand Tombal; Giansilvio Marchioro; Jochen Walz; Burkhard Kneitz; Pia Bader; Detlef Frohneberg; Alessandro Tizzani; Markus Graefen; Paul van Cangh; R Jeffrey Karnes; Francesco Montorsi; Hein Van Poppel; Martin Spahn Journal: Eur Urol Date: 2014-01-25 Impact factor: 20.096
Authors: Lauren Barber; Travis Gerke; Sarah C Markt; Samuel F Peisch; Kathryn M Wilson; Thomas Ahearn; Edward Giovannucci; Giovanni Parmigiani; Lorelei A Mucci Journal: Clin Cancer Res Date: 2018-08-06 Impact factor: 12.531
Authors: John R Prensner; Matthew K Iyer; Anirban Sahu; Irfan A Asangani; Qi Cao; Lalit Patel; Ismael A Vergara; Elai Davicioni; Nicholas Erho; Mercedeh Ghadessi; Robert B Jenkins; Timothy J Triche; Rohit Malik; Rachel Bedenis; Natalie McGregor; Teng Ma; Wei Chen; Sumin Han; Xiaojun Jing; Xuhong Cao; Xiaoju Wang; Benjamin Chandler; Wei Yan; Javed Siddiqui; Lakshmi P Kunju; Saravana M Dhanasekaran; Kenneth J Pienta; Felix Y Feng; Arul M Chinnaiyan Journal: Nat Genet Date: 2013-09-29 Impact factor: 38.330
Authors: Michael Rose; Vera Kloten; Erik Noetzel; Lukas Gola; Josef Ehling; Timon Heide; Steffen K Meurer; Aljona Gaiko-Shcherbak; Antonio S Sechi; Sebastian Huth; Ralf Weiskirchen; Oliver Klaas; Wiebke Antonopoulos; Qiong Lin; Wolfgang Wagner; Jürgen Veeck; Felix Gremse; Julia Steitz; Ruth Knüchel; Edgar Dahl Journal: Mol Cancer Date: 2017-02-23 Impact factor: 27.401
Authors: Christine J Kurian; Amy E Leader; Melissa S Y Thong; Scott W Keith; Charnita M Zeigler-Johnson Journal: BMC Public Health Date: 2018-08-23 Impact factor: 3.295
Authors: Marina Kazantseva; Sunali Mehta; Ramona A Eiholzer; Gregory Gimenez; Sara Bowie; Hamish Campbell; Ashley L Reily-Bell; Imogen Roth; Sankalita Ray; Catherine J Drummond; Glen Reid; Sebastien M Joruiz; Anna Wiles; Helen R Morrin; Karen L Reader; Noelyn A Hung; Margaret A Baird; Tania L Slatter; Antony W Braithwaite Journal: Cell Death Dis Date: 2019-08-20 Impact factor: 8.469